Physician profile
Jorge Simental
NPI 1578155099
$5,872.16
in general payments reported to CMS, 2019-2025
29 companies · $2,971 in 2025
The $2,971 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $243 · 2022: $182 · 2023: $214 · 2024: $2,262 · 2025: $2,971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,720 · Food and Beverage: $2,476 · Consulting Fee: $150 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,719.90 |
| Food and Beverage | $2,476.02 |
| Consulting Fee | $150.00 |
| Education | $101.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $3,898.02 | 2024-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $300.50 | 2023-2025 | Airsupra, Fasenra, Breztri |
| Jazz Pharmaceuticals INC. | $276.43 | 2025 | |
| Genzyme Corporation | $167.19 | 2024-2025 | |
| Harmony Biosciences LLC | $142.89 | 2025 | |
| Titan Surgical Group, LLC | $100.06 | 2022 | |
| Pulmonx Corporation | $79.19 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Glaxosmithkline, LLC. | $78.19 | 2024-2025 | Trelegy Ellipta, Arexvy, Nucala |
| United Therapeutics Corporation | $73.41 | 2025 | Tyvaso |
| Abbvie INC. | $71.52 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $70.07 | 2025 | Dupixent |
| Novo Nordisk INC | $65.36 | 2021-2022 | |
| Amgen INC. | $63.34 | 2021-2025 | Tezspire |
| Pfizer INC. | $62.02 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $56.18 | 2024 | Uptravi, Opsumit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $52.34 | 2025 | Sunosi |
| Verona Pharma, INC. | $51.45 | 2025 | Ohtuvayre |
| Resmed Corp | $46.81 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $40.34 | 2021-2024 | Winrevair |
| Grifols USA, LLC | $29.90 | 2024-2025 | Prolastin-C Liquid |
| Sanofi Pasteur INC. | $25.13 | 2021-2022 | |
| Electromed, INC. | $21.17 | 2025 | Smartvest |
| Viatris Specialty LLC | $17.12 | 2025 | Yupelri |
| Exact Sciences Corporation | $16.92 | 2023 | Cologuard Collection Kit |
| Avadel Cns Pharmaceuticals, LLC | $16.15 | 2024 | Lumryz |
| Idorsia Pharmaceuticals US INC | $14.90 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $14.06 | 2021 | |
| Lilly USA, LLC | $12.55 | 2021 | |
| Genentech USA, INC. | $8.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Simental listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.